Circulating Th17 are increased in patients with ankylosing spondylitis (AS), a prototype of axSpA (4), but this can be effectively attenuated with tumor necrosis factor (TNF) inhibitors (5). This evidence concerns the gene TNF and ankylosing spondylitis.